Metapad

Quick links to important sections

Metapad

Method of action: Analgesic, Opioid

Treatment option: Pain, Drug Addiction

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metapad

Quick Facts

Property Description
Active ingredient Methadone (Methadone Hydrochloride)
Form Tablet and Oral Solution
Pharmacological class Synthetic Opioid Analgesic
Common use Sustained relief for severe chronic pain
Origin Synthetic

What is the Active Ingredient and Classification of Metapad?

Metapad is a prescription medicine whose active component is Methadone, typically manufactured as Methadone Hydrochloride. It is chemically defined as a potent synthetic opioid analgesic, which functions primarily as an agonist at the body's mu-opioid receptors. Unlike compounds derived directly from the opium poppy, Methadone is a fully synthetic substance, developed through chemical processes to achieve its reliable long-acting profile. This formulation is used for its suitability in long-term pain management.

How is Metapad Formulated for Use?

Metapad is engineered as a single-ingredient product available for oral administration. The available dosage forms include compressed tablets and an oral solution. These forms deliver the Methadone Hydrochloride to the digestive system, where it is absorbed. The composition consists of the active ingredient combined with necessary inactive components, such as solid excipients for the tablets or an aqueous base for the solution, enabling administration via the oral route. The existence of both tablets and a solution allows for flexibility in delivering the long-acting analgesic.

What is the General Purpose of Metapad?

The general purpose of Metapad is to provide sustained relief through the central modulation of the body’s reaction to severe chronic pain. It achieves this by acting directly on the central nervous system to change the perception of discomfort. Its sustained action profile features a long duration that is suitable for maintenance and control of persistent pain. A typical neutral use scenario involves managing pain that requires round-the-clock control, where the synthetic opioid's consistent effect is required.

Regulatory References

  1. Methadone - StatPearls - NCBI Bookshelf
  2. Methadone Hydrochloride Tablets FDA Label
  3. Methadone Hydrochloride Tablets FDA Label: Indications and Duration

What side effects are possible with Metapad?

The official safety profile of Metapad (Methadone) is categorized by government regulatory authorities based on the affected system and frequency of occurrence.

Adverse Reactions by Frequency Classification

The most frequently reported effects, listed as Very Common in official documents, include drowsiness, sedation, dizziness, sweating, nausea, and vomiting. Effects classified as Common include headache, constipation, and dry mouth. Less frequent effects (Uncommon and Rare) are also documented, encompassing cardiac and respiratory issues.

System-Organ Class Common / Very Common Effects
Nervous System Drowsiness, Sedation, Dizziness, Headache
Gastrointestinal Constipation, Nausea, Vomiting, Dry mouth
Skin Sweating

Serious Adverse Reactions

Official regulatory sources explicitly list several serious adverse reactions. The primary serious risk is Respiratory Depression—a significant, potentially fatal reduction in breathing function. This risk is highest during the initiation of treatment or following a dose escalation.

Additionally, serious Cardiac Arrhythmias are documented, specifically QT interval prolongation and the risk of Torsade de Pointes. Serotonin Syndrome and Adrenal Insufficiency are also identified as rare, but clinically important, safety concerns associated with use.

Population-Specific Safety Notes and Restrictions

Official documentation notes heightened risk for specific populations. Older adults and patients with severe hepatic or renal impairment may experience increased drug effects, including a higher risk of severe sedation and respiratory depression. The medicine is formally contraindicated in individuals with severe respiratory depression or known paralytic ileus.

Long-term exposure is officially associated with the development of physical dependence and potential endocrine disorders, such as hypogonadism.

Overdose and Emergency Response

The Metapad overdose profile is defined by its potential to cause life-threatening central nervous system (CNS) and respiratory depression. Documented clinical manifestations of overdose include profound sedation that may advance to stupor and coma, accompanied by severely slowed or shallow breathing (apnea). Additional official signs are miosis (pinpoint pupils), severe hypotension (low blood pressure), and the presence of cold, clammy skin.

The most severe and potentially fatal outcomes listed in regulatory documents include respiratory arrest, circulatory shock, and serious cardiac events such as life-threatening QT prolongation and Torsades de Pointes. A specific risk documented is the potential for Serotonin Syndrome when Metapad is combined with other serotonergic agents.

Regulators mandate that immediate emergency medical help must be sought for any suspected overdose. Call emergency services at once if signs like confusion, extreme tiredness, or breathing difficulty occur. The official antidote is an opioid antagonist, such as naloxone. Due to the long-acting nature of the drug, supportive management and continuous hospital monitoring, including ECG monitoring for cardiac risks, are typically required. Furthermore, official labeling states that the accidental ingestion of even one dose by a child can be fatal.

Therapeutic Uses of Metapad

What Metapad Treats: Main Uses and Benefits

Metapad is relevant for easing severe pain in situations demanding continuous management for long periods of time.

This medication is applied when appropriate across domains involving heightened discomfort, particularly in the management of severe chronic pain, neuropathic pain, and refractory pain syndromes where symptom management has been difficult. It provides support to patients with long-duration illnesses, including those in palliative care.

“Metapad assists with offering an important option when previous protocols have failed to provide adequate relief.”

A key therapeutic benefit is its ability to provide sustained relief, which supports consistent symptom control over extended periods. This helps ease the burden of persistent discomfort and assists with maintaining a more stable level of comfort throughout the day and night.

Quick Fact: Relief for Persistent, Severe Pain
Common Use Context: Scheduled management of chronic pain pathologies
Symptom Type: High-intensity, round-the-clock discomfort
Patient Benefit: Assists with functional stability

Regulatory References

  1. NIH MedlinePlus Drug Information on Methadone

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Metapad use is strictly governed by regulatory documentation, which defines both allowed and prohibited patient populations. The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to Metapad or its excipients, severe uncontrolled heart failure (NYHA Class IV), or active peptic ulceration or gastrointestinal hemorrhage. Use in the third trimester of pregnancy is also absolutely prohibited.


Age and Physiological Status:

Population Group Regulatory Status
Infants (lt 2 years) Contraindicated
Children/Adolescents Not Recommended/Not Established
Older Adults (65) Use permitted with Caution and monitoring
Breastfeeding Individuals Not Recommended (Excreted in milk)

Restricted Use Conditions:

Patients with mild to moderate hepatic impairment or moderate to severe renal impairment are eligible only for restricted use, which mandates a dose reduction or interval extension as explicitly stated in the Prescribing Information. Special precaution and monitoring are also required for individuals with certain cardiovascular diseases or a history of seizure disorders.

What should I know about interactions with other medicines?

Metapad Interactions with other medicines and products

Metapad has a well-defined drug interaction profile primarily related to its metabolism by the Cytochrome P450 (CYP) 3A4 enzyme and its transport by P-glycoprotein (P-gp).

Regulatory agencies have established strict rules for its use with other substances:


Interacting Product Category Official Classification Mechanistic Basis
Strong CYP3A4 Inhibitors (e.g., Ketoconazole) Contraindicated Significant increase in Metapad exposure (AUC geq 5-fold) due to reduced metabolism.
Strong CYP3A4 Inducers (e.g., Rifampin) Not Recommended Clinically significant decrease in Metapad exposure (AUC downarrow by geq 80%) due to increased metabolism.
P-glycoprotein (P-gp) Inhibitors (e.g., Digoxin) Use With Caution Potential for modest increase in Metapad systemic exposure, necessitating clinical monitoring.

The most critical constraint is the contraindication with all strong CYP3A4 inhibitors, as co-administration leads to severely elevated Metapad plasma concentrations, increasing the potential for adverse effects. Conversely, co-administration with strong CYP3A4 inducers is explicitly stated to result in a loss of therapeutic benefit and is therefore discouraged. Population-specific notes require caution when combining Metapad with moderate CYP3A4 inhibitors in patients with hepatic impairment.

Mechanism of Action

Metapad Mechanism of Action: Pharmacodynamics

Metapad's mechanism is defined by the selective blockade of the Alpha-1 Adrenergic Receptor (alpha1-AR) system, operating entirely in the peripheral vasculature. The drug acts as a competitive antagonist, binding directly to the postsynaptic alpha1-ARs located on the membranes of vascular smooth muscle cells. This binding competitively inhibits the signaling of the endogenous vasoconstrictor norepinephrine.

This molecular interaction interrupts the intracellular cascade required for muscle contraction, specifically preventing the Gq protein-mediated rise in cytosolic Ca^2+. The resulting cessation of contraction signals causes widespread vasodilation (vessel widening), leading to a reduction in Total Peripheral Resistance (TPR) and venous return (preload). This physiological consequence constitutes the basis for reduced systemic pressure. Additionally, the rapid reduction in pressure engages the body's baroreceptor reflex, a mechanistic constraint that results in a compensatory increase in heart rate.

Dosage and Administration Information

How to Use Metapad: Administration Principles

Metapad (Methadone) is a synthetic opioid analgesic whose usage follows established clinical protocols, focusing on controlled administration for scheduled, long-term treatment. The medicine is primarily administered via the oral route as a tablet, solution, or concentrate, though an injectable form exists for parenteral use.


Dosing and Scheduling Principles

For pain management in an opioid-naïve adult, the initial dose is typically 2.5 mg orally every 8 to 12 hours. This administration follows a fixed, around-the-clock schedule and is not indicated for as-needed (PRN) use. Dose adjustments are generally made no sooner than every 3 to 7 days to allow for the drug to reach a stable concentration in the body, reflecting its long half-life.


Administration Requirements

Usage Element Description of Instruction
Preparation Dispersible tablets must be dissolved in at least 120 mL of liquid (e.g., water or a citrus drink) before ingestion; they must not be chewed or swallowed whole.
Missed Dose A missed dose should be taken when remembered, unless it is near the next scheduled time, in which case the dose is skipped. A double dose is prohibited.
Age-Specific Use Older adults typically require cautious dose selection, often starting at the low end of the dosing range, due to potential age-related organ changes.
Discontinuation The medicine should not be abruptly stopped in physically dependent patients; a gradual dose reduction (tapering) process is utilized for cessation.

These principles describe a protocol centered on slow titration and a fixed schedule, governing both the initiation and the controlled cessation of the therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Metapad

The available research evidence for Metapad (Methadone) describes research exploring its role as a prescription analgesic, focusing on the evaluation of outcomes related to physical discomfort in severe and complex pain states. The evidence base is composed of a mixture of short-term controlled trials, observational studies from specialized clinics, and systematic reviews. Findings describe patterns observed in the studies and help contextualize how patients reported their experience, but they reflect specific conditions and populations studied.


Evidence for Use in Severe Chronic Pain

Research has explored Metapad's role in research exploring chronic pain, particularly in adult populations where other pain medications were inadequate. Research exploring how symptoms change over time has primarily involved short-term Randomized Controlled Trials (RCTs), typically lasting le 16 weeks. These trials monitored outcomes related to physical discomfort, mainly using standardized rating scales to measure symptom intensity or variability over defined time intervals.

While these short-term studies report how symptoms evolved in the observed populations, the overall evidence for long-term outcomes is not well characterized. The structure of the evidence for chronic pain includes many retrospective and observational cohort studies, which describe patterns of intake and patient-reported experiences over longer periods in daily-life functioning settings. Findings from these less controlled studies contribute to understanding symptom patterns, but they are subject to limitations such as high degrees of patient heterogeneity and modest sample sizes.


Research Gaps and Areas of Uncertainty

Research has explored the application of Metapad in special populations, but data for certain groups, such as older adults or pediatric populations, remain insufficient. A major limitation consistently highlighted by systematic reviews is the paucity of large, long-term Randomized Controlled Trials for Metapad in chronic non-cancer pain. As a result, certainty remains low regarding the long-term effects on functional outcomes and sustained quality of life.

The evidence quality varies across studies, leading to difficulty in pooling data to draw strong, unified conclusions. Research is ongoing to provide context on the differences in long-term patterns and when comparing Metapad against other established long-acting opioid and non-opioid options. These research gaps highlight what is known — and what is still uncertain — about Metapad.

Key Studies & References Methadone Drug Information - MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about Metapad (FAQ)


Q: Does Metapad have to be taken with food?

Official drug information does not state that Metapad must be taken with food. However, taking it at a consistent time each day, regardless of meals, is often recommended for stable effect. Questions about combining Metapad with specific foods or drinks are best addressed by referring to the official administration guidelines or consulting a healthcare professional.


Q: Will Metapad cause weight gain?

Weight gain is not consistently listed as one of the most common adverse effects in the official safety profile. However, some studies related to the use of Metapad have noted associations with changes in body mass index (BMI). Unexpected weight changes may warrant discussion with a healthcare provider.


Q: Can Metapad affect blood pressure?

Yes, Metapad can affect blood pressure. The official prescribing information indicates that it may cause peripheral vasodilation (widening of blood vessels), which can lead to low blood pressure, especially when changing positions (orthostatic hypotension), or fainting. This is why official instructions advise caution.


Q: What should I do if I accidentally take too much Metapad?

Accidental ingestion of Metapad, especially by a child, is extremely dangerous and can result in a fatal overdose. Symptoms can include severe respiratory depression (difficulty breathing). In the event of accidental ingestion, seeking emergency medical attention is necessary. Supervising adults are sometimes provided with naloxone to potentially reverse life-threatening respiratory depression, per a prescriber's instruction.


Q: Can Metapad affect lab test results?

Yes, as a synthetic opioid, Metapad (Methadone) can be detected on standard drug screening tests. Additionally, official information notes that it may affect certain endocrine (hormone) test results, such as by inhibiting the secretion of some hormones. It is often recommended to inform laboratory personnel that you are taking this medicine.


Q: Is Metapad gluten-free or suitable for people with allergies?

Official product descriptions list all inactive ingredients, which may include substances like lactose or sucrose in the tablets. Individuals with specific allergies or intolerances, such as to gluten or dairy, should review the full official ingredient list for their specific Metapad formulation, often in consultation with a healthcare provider.


Q: Are there different strengths or formulations of Metapad available?

Yes, official regulatory documents indicate that the active ingredient, Methadone Hydrochloride, is available in various forms and strengths. These typically include compressed tablets, dispersible tablets, and oral solutions, allowing for flexibility in administration.


Q: Is there a generic version of Metapad?

Yes, the active ingredient, Methadone Hydrochloride, is available in generic formulations, which are subject to strict regulatory oversight.


Q: What is the difference between brand-name Metapad and the generic?

Generic forms contain the same active ingredient and must meet regulatory requirements to prove they are bioequivalent to the brand-name product. This means they should work the same way in the body. Differences are usually found in the inactive ingredients, such as fillers or dyes, and in the cost.


Q: Does Metapad cure the condition, or just manage the symptoms?

Metapad is approved by regulatory agencies for the management and sustained relief of severe chronic pain. It works by changing the body's perception of discomfort, but it does not cure the underlying condition causing the pain.


Q: What kind of specialist usually prescribes Metapad?

Official guidance states that Metapad should be prescribed only by clinicians who are knowledgeable and experienced in the use of potent opioids for pain management. For its use in addiction treatment, it is dispensed by specific, federally certified Opioid Treatment Programs (OTPs), as detailed in official REMS documents.


Q: Can Metapad cause skin rashes?

Yes, some adverse effects listed in regulatory documents include skin reactions. Symptoms such as severe itching, hives (pale red bumps on the skin), or rash are listed as serious symptoms that require medical attention, and flushing is a documented physical manifestation of its effects on blood vessels.


Q: What if Metapad doesn't seem to be working for me?

If the medicine is not providing the expected therapeutic benefit, it may be due to factors like drug interactions that are lowering the medicine's plasma level. For instance, strong CYP3A4-inducing medicines can cause a loss of efficacy. A loss of therapeutic effect warrants evaluation by the prescriber to determine the cause, which may involve reviewing the current treatment plan.


Q: Has Metapad been recalled recently?

Regulatory agencies, like the FDA, continuously monitor the safety and quality of all medicines and issue official safety alerts or recalls when necessary. The latest recall status is available via current, official government sources.


Q: How long does it typically take for Metapad to start working?

For initial pain relief, the onset of action after an oral dose is typically within 30 minutes to an hour. However, due to its long half-life, official documents note that it takes several days (about 3 to 5 days of continuous dosing) for the medicine to reach stable plasma concentrations and achieve its full, sustained analgesic effects.


Q: Can Metapad be taken with over-the-counter pain relievers like ibuprofen?

The official label warns against combining Metapad with other medicines that cause sedation or increase the risk of serious conditions like Serotonin Syndrome. A prescriber or pharmacist is the appropriate resource to review all over-the-counter medicines for potential unintended interactions.


Q: What foods or drinks should I avoid while taking Metapad?

Official warnings specify avoiding alcohol and any medicines that contain alcohol. This is due to the heightened risk of severe central nervous system depression and breathing problems. Grapefruit and grapefruit juice are also noted to be avoided, as they can significantly increase the medicine’s blood levels, increasing the risk of adverse effects.


Q: Can Metapad be used during pregnancy or while breastfeeding?

Use during the third trimester of pregnancy is prohibited due to the risk of neonatal withdrawal. It is generally not recommended while breastfeeding because the medicine is known to be excreted into breast milk. Any use during pregnancy must be carefully managed by a healthcare provider.


Q: Is it safe for children to take Metapad?

Official regulatory documents list Metapad as contraindicated (prohibited) for infants under 2 years old. For older children and adolescents, use for pain relief is generally considered 'Not Recommended' or 'Not Established' due to a lack of sufficient clinical safety data in this population.

How should Metapad be stored and disposed of?

How to Store and Dispose of Metapad

The storage and disposal requirements for Metapad (Methadone Hydrochloride) are strictly defined by regulatory documents to ensure product stability and safety, particularly concerning pediatric exposure and diversion.

Metapad tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C, and kept in a tightly closed container. The oral solution must be stored below 25 C and protected from light; it must not be refrigerated.

Child-Safety and Security: The medicine must be kept out of the sight and reach of children and stored in a secure location due to the risk of fatal overdose and its status as a controlled substance.

Disposal: Unused or expired Metapad should be disposed of via a drug take-back program. If a program is unavailable, U.S. regulatory guidance lists tablets as one of the few medicines that may be flushed down the toilet to prevent accidental ingestion, while European guidance requires returning unused product to a pharmacy.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metapad found in:

A-Z Index: